

HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)

General Information

Synonyms: MHC;Hepatitis B virus;HBV

Protein Construction: Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and FLLTRILTI peptide. Tetramer is assembled by biotinylated monomer and streptavidin.

Species: Human

Expression Host: HEK293 Cells

Accession: A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTI peptide

Molecular Weight: The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.

QC Testing

Biological Activity: Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.

Purity: > 95% as determined by Tris-Bis PAGE; > 93% as determined by HPLC

Endotoxin: < 1 EU/μg by the LAL method.

Formulation: Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Shipping:

In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.

Protein Background

Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).

Reference

Ciccozzi M, et al. Evolutionary dynamics of HBV-D1 genotype epidemic in Turkey. *J Med Virol.* 2014 Jan;86:109-16. doi: 10.1002/jmv.23740. Epub 2013 Oct 24. PMID: 24243521.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_email:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481